vs
奥尼兰姆制药（ALNY）与MADRIGAL PHARMACEUTICALS, INC.（MDGL）财务数据对比。点击上方公司名可切换其他公司
奥尼兰姆制药的季度营收约是MADRIGAL PHARMACEUTICALS, INC.的3.4倍（$1.1B vs $321.1M），奥尼兰姆制药净利率更高（17.0% vs -18.2%，领先35.2%），MADRIGAL PHARMACEUTICALS, INC.同比增速更快（210.8% vs 84.9%），奥尼兰姆制药自由现金流更多（$140.3M vs $-133.8M）
奥尼兰姆制药是美国生物制药企业，2002年成立，总部位于马萨诸塞州剑桥市，专注于研发及商业化针对基因明确疾病的RNA干扰（RNAi）疗法，2016年入选福布斯「100家最具创新力成长企业」榜单。
本公司是一家美国生物制药企业，成立于2002年，专注于研发新型合成胆汁酸类似物，可用于治疗原发性胆汁性胆管炎、非酒精性脂肪肝、肝硬化等慢性肝病，以及胆汁酸性腹泻等肠道疾病。
ALNY vs MDGL — 直观对比
营收规模更大
ALNY
是对方的3.4倍
$321.1M
营收增速更快
MDGL
高出125.8%
84.9%
净利率更高
ALNY
高出35.2%
-18.2%
自由现金流更多
ALNY
多$274.1M
$-133.8M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $321.1M |
| 净利润 | $186.4M | $-58.6M |
| 毛利率 | 75.6% | — |
| 营业利润率 | 12.0% | -18.6% |
| 净利率 | 17.0% | -18.2% |
| 营收同比 | 84.9% | 210.8% |
| 净利润同比 | 322.6% | 1.4% |
| 每股收益（稀释后） | $1.44 | $-2.55 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALNYMDGL
| Q4 25 | $1.1B | $321.1M | ||
| Q3 25 | $1.2B | $287.3M | ||
| Q2 25 | $773.7M | $212.8M | ||
| Q1 25 | $594.2M | $137.3M | ||
| Q4 24 | $593.2M | $103.3M | ||
| Q3 24 | $500.9M | $62.2M | ||
| Q2 24 | $659.8M | — | ||
| Q1 24 | $494.3M | $0 |
净利润ALNYMDGL
| Q4 25 | $186.4M | $-58.6M | ||
| Q3 25 | $251.1M | $-114.2M | ||
| Q2 25 | $-66.3M | $-42.3M | ||
| Q1 25 | $-57.5M | $-73.2M | ||
| Q4 24 | $-83.8M | $-59.4M | ||
| Q3 24 | $-111.6M | $-107.0M | ||
| Q2 24 | $-16.9M | — | ||
| Q1 24 | $-65.9M | $-147.5M |
毛利率ALNYMDGL
| Q4 25 | 75.6% | — | ||
| Q3 25 | 84.2% | — | ||
| Q2 25 | 81.6% | — | ||
| Q1 25 | 88.2% | 96.7% | ||
| Q4 24 | 82.7% | — | ||
| Q3 24 | 83.6% | — | ||
| Q2 24 | 89.8% | — | ||
| Q1 24 | 89.0% | — |
营业利润率ALNYMDGL
| Q4 25 | 12.0% | -18.6% | ||
| Q3 25 | 29.5% | -39.7% | ||
| Q2 25 | -2.1% | -22.2% | ||
| Q1 25 | 3.0% | -57.8% | ||
| Q4 24 | -17.7% | -64.8% | ||
| Q3 24 | -15.4% | -187.1% | ||
| Q2 24 | 7.4% | — | ||
| Q1 24 | -8.8% | — |
净利率ALNYMDGL
| Q4 25 | 17.0% | -18.2% | ||
| Q3 25 | 20.1% | -39.8% | ||
| Q2 25 | -8.6% | -19.9% | ||
| Q1 25 | -9.7% | -53.4% | ||
| Q4 24 | -14.1% | -57.5% | ||
| Q3 24 | -22.3% | -172.0% | ||
| Q2 24 | -2.6% | — | ||
| Q1 24 | -13.3% | — |
每股收益（稀释后）ALNYMDGL
| Q4 25 | $1.44 | $-2.55 | ||
| Q3 25 | $1.84 | $-5.08 | ||
| Q2 25 | $-0.51 | $-1.90 | ||
| Q1 25 | $-0.44 | $-3.32 | ||
| Q4 24 | $-0.66 | $-2.50 | ||
| Q3 24 | $-0.87 | $-4.92 | ||
| Q2 24 | $-0.13 | — | ||
| Q1 24 | $-0.52 | $-7.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.7B | $198.7M |
| 总债务越低越好 | — | $339.9M |
| 股东权益账面价值 | $789.2M | $602.7M |
| 总资产 | $5.0B | $1.3B |
| 负债/权益比越低杠杆越低 | — | 0.56× |
8季度趋势，按日历期对齐
现金及短期投资ALNYMDGL
| Q4 25 | $1.7B | $198.7M | ||
| Q3 25 | $1.5B | $295.7M | ||
| Q2 25 | $1.1B | $186.2M | ||
| Q1 25 | $1.0B | $183.6M | ||
| Q4 24 | $966.4M | $100.0M | ||
| Q3 24 | $1.1B | $232.7M | ||
| Q2 24 | $968.5M | — | ||
| Q1 24 | $681.9M | $622.5M |
总债务ALNYMDGL
| Q4 25 | — | $339.9M | ||
| Q3 25 | — | $339.8M | ||
| Q2 25 | — | $118.4M | ||
| Q1 25 | — | $118.0M | ||
| Q4 24 | — | $117.6M | ||
| Q3 24 | — | $117.1M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $116.1M |
股东权益ALNYMDGL
| Q4 25 | $789.2M | $602.7M | ||
| Q3 25 | $233.9M | $625.7M | ||
| Q2 25 | $250.6M | $696.0M | ||
| Q1 25 | $115.4M | $710.6M | ||
| Q4 24 | $67.1M | $754.4M | ||
| Q3 24 | $32.4M | $777.2M | ||
| Q2 24 | $-3.1M | — | ||
| Q1 24 | $-219.3M | $850.8M |
总资产ALNYMDGL
| Q4 25 | $5.0B | $1.3B | ||
| Q3 25 | $4.9B | $1.4B | ||
| Q2 25 | $4.6B | $1.0B | ||
| Q1 25 | $4.2B | $996.6M | ||
| Q4 24 | $4.2B | $1.0B | ||
| Q3 24 | $4.2B | $1.1B | ||
| Q2 24 | $4.0B | — | ||
| Q1 24 | $3.8B | $1.1B |
负债/权益比ALNYMDGL
| Q4 25 | — | 0.56× | ||
| Q3 25 | — | 0.54× | ||
| Q2 25 | — | 0.17× | ||
| Q1 25 | — | 0.17× | ||
| Q4 24 | — | 0.16× | ||
| Q3 24 | — | 0.15× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $163.6M | $-133.5M |
| 自由现金流经营现金流 - 资本支出 | $140.3M | $-133.8M |
| 自由现金流率自由现金流/营收 | 12.8% | -41.7% |
| 资本支出强度资本支出/营收 | 2.1% | 0.1% |
| 现金转化率经营现金流/净利润 | 0.88× | — |
| 过去12个月自由现金流最近4个季度 | $465.4M | — |
8季度趋势，按日历期对齐
经营现金流ALNYMDGL
| Q4 25 | $163.6M | $-133.5M | ||
| Q3 25 | $325.1M | $79.8M | ||
| Q2 25 | $153.7M | $-47.1M | ||
| Q1 25 | $-118.3M | $-88.9M | ||
| Q4 24 | $-94.7M | $-104.5M | ||
| Q3 24 | $43.7M | $-67.0M | ||
| Q2 24 | $124.2M | — | ||
| Q1 24 | $-81.5M | $-149.2M |
自由现金流ALNYMDGL
| Q4 25 | $140.3M | $-133.8M | ||
| Q3 25 | $313.0M | $79.0M | ||
| Q2 25 | $139.4M | — | ||
| Q1 25 | $-127.3M | — | ||
| Q4 24 | $-103.8M | $-104.7M | ||
| Q3 24 | $39.5M | $-67.8M | ||
| Q2 24 | $116.1M | — | ||
| Q1 24 | $-94.5M | $-149.5M |
自由现金流率ALNYMDGL
| Q4 25 | 12.8% | -41.7% | ||
| Q3 25 | 25.1% | 27.5% | ||
| Q2 25 | 18.0% | — | ||
| Q1 25 | -21.4% | — | ||
| Q4 24 | -17.5% | -101.3% | ||
| Q3 24 | 7.9% | -109.0% | ||
| Q2 24 | 17.6% | — | ||
| Q1 24 | -19.1% | — |
资本支出强度ALNYMDGL
| Q4 25 | 2.1% | 0.1% | ||
| Q3 25 | 1.0% | 0.3% | ||
| Q2 25 | 1.8% | 0.0% | ||
| Q1 25 | 1.5% | 0.0% | ||
| Q4 24 | 1.5% | 0.2% | ||
| Q3 24 | 0.8% | 1.3% | ||
| Q2 24 | 1.2% | — | ||
| Q1 24 | 2.6% | — |
现金转化率ALNYMDGL
| Q4 25 | 0.88× | — | ||
| Q3 25 | 1.29× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALNY
| TTR | $858.3M | 78% |
| Rare | $136.4M | 12% |
| GIVLAARI | $56.3M | 5% |
| Collaborative Arrangement | $40.9M | 4% |
| ONPATTRO | $12.0M | 1% |
MDGL
| Rebates Customer Fees Credits Co Pay Assistance And Other | $208.5M | 65% |
| Other | $76.0M | 24% |
| Chargebacks Discounts For Prompt Pay And Other Allowances | $36.6M | 11% |
